Sunesis to Host Analyst & Institutional Investor Meeting on October 4, 2012
September 27 2012 - 6:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that
the Company will host an analyst and institutional investor meeting
on Thursday, October 4, 2012, from 5:00 to 6:30 PM Eastern Time in
New York City. The event will include an overview of vosaroxin and
the VALOR trial, a pivotal Phase 3, randomized, controlled,
double-blind, multinational clinical trial in first relapsed or
refractory acute myeloid leukemia (AML), as well as the Less
Intensive 1 (LI-1) Study being conducted by the United Kingdom's
National Cancer Research Institute (NCRI) Haematological Oncology
Study Group.
The event will be moderated by Daniel Swisher, Chief Executive
Officer of Sunesis, and will include presentations by, and an in
depth panel discussion with, key opinion leaders in AML, including
VALOR principal investigators. Presentations will be followed by a
question and answer session.
The panel will include:
- Alan K. Burnett, MD, Professor of Medicine, Head of
Haematology, Department of Medical Genetics, Haematology and
Pathology at Cardiff University School of Medicine;
- Eric Feldman, MD, Chair of the VALOR Steering Committee,
Professor of Medicine and Director of the Leukemia Program and
Hematological Malignancies at Weill Cornell Medical College;
and
- Farhad Ravandi, MD, a principal investigator of VALOR,
Professor of Medicine, Department of Leukemia, Division of Cancer
Medicine, The University of Texas MD Anderson Cancer Center.
A live webcast of the event will be available on the Sunesis
website at http://ir.sunesis.com. A replay of the webcast will be
archived on the "Calendar of Events" page in the Investors and
Media section of the Sunesis website following the event.
About VALOR
VALOR is a Phase 3, randomized, double-blind,
placebo-controlled, pivotal trial in patients with first relapsed
or refractory AML. The trial's target enrollment is 675 patients at
more than 110 leading sites in the U.S., Canada, Europe, Australia
and New Zealand. The VALOR trial is currently enrolling patients,
who are randomized one to one to receive either vosaroxin on days
one and four in combination with cytarabine daily for five days, or
placebo in combination with cytarabine. The trial's primary
endpoint is overall survival. For more information on the VALOR
trial, please visit www.valortrial.com.
About Vosaroxin
Vosaroxin is a first-in-class anti-cancer quinolone derivative
(AQD), a class of compounds that has not been used previously for
the treatment of cancer. Vosaroxin both intercalates DNA and
inhibits topoisomerase II, resulting in replication-dependent,
site-selective DNA damage, G2 arrest and apoptosis. Both the U.S.
Food and Drug Administration (FDA) and European Commission have
granted orphan drug designation to vosaroxin for the treatment of
acute myeloid leukemia. Additionally, vosaroxin has been granted
fast track designation by the FDA for the potential treatment of
relapsed or refractory acute myeloid leukemia in combination with
cytarabine.
About AML
AML is a rapidly progressing cancer of the blood characterized
by the uncontrolled proliferation of immature blast cells in the
bone marrow. The American Cancer Society estimates there will be
approximately 13,780 new cases of AML and 10,200 deaths from AML in
the U.S. in 2012. Additionally, it is estimated that the
prevalence of AML across major global markets (U.S., France,
Germany, Italy, Spain, United Kingdom, and Japan) is over 50,000.
AML is generally a disease of older adults, and the median age of a
patient diagnosed with AML is about 67 years. AML patients with
relapsed or refractory disease and newly diagnosed AML patients
over 60 years of age with poor prognostic risk factors typically
die within one year, resulting in an acute need for new treatment
options for these patients.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers. Sunesis has built a
highly experienced cancer drug development organization committed
to advancing its lead product candidate, vosaroxin, in multiple
indications to improve the lives of people with cancer. For
additional information on Sunesis, please visit
http://www.sunesis.com.
The Sunesis Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8773
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals,
Inc.
CONTACT: Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2023 to Aug 2024